Sidebar

imo RVX/Eversana are not capable of handling mfg, distribution, marketing, product liability & support for a blockbuster. BP needs to take them out & roll with this new science. The star factory is their bonus & upside. I see an offer of 10-12 bil or $35-40 US per share for Apabetalone and all of RVX and Zenith combined. Each compound must be tested approved and supported. Think of the legal liability and risk alone for just Apabetalone - a high end cardiovascular product. RVX can't handle the support for worldwide distribution even with Eversana. The product needs FDA approval or EUA and RVX will be taken out.

jmo

Chicagoest